Abrégé

The present invention relates to the use of the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof in the treatment of SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer. More specifically, the present invention provides to the use of pharmaceutical compositions comprising the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof and at least one physiologically acceptable excipient in the treatment of a patient affected by SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer.

Classes IPC  ?

• A61K 38/12 - Peptides cycliques
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as “gene expression signatures”, in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Produits et services

Pharmaceutical compositions; pharmaceutical preparations; pharmaceutical preparations for rare diseases; Diagnostic preparations and materials, for medical and veterinary purposes; Dietetic substances adapted for medical use; Dietetic foods adapted for medical purposes; Dietary supplements for human beings. Marketing studies; business investigations; organisation of exhibitions for commercial or advertising purposes; publication of publicity texts; market research; business research; public relations; provision of business statistical information. Science and technology services; Technical research; Scientific services and design relating thereto; Technological services and design relating thereto; Scientific research; Industrial analysis and research services; Technological consultancy; Medical research; Research and development services in the field of chemistry; Pharmaceutical research services; Development of pharmaceutical preparations and medicines; Medical and pharmacological research services; Research and development in the field of biotechnology; Pharmaceutical product evaluation. Health counselling; pharmacy advice; professional consultancy relating to health; professional consultancy relating to health care; providing medical information; providing medical information in the healthcare sector; providing information relating to medical services; providing news and information in the field of medicine; providing health information; medical information; medical equipment rental; rental of equipment for medical purposes; hiring of medical instruments; medical screening services in the field of asthma; medical services for the treatment of conditions of the human body; medical screening; pharmaceutical services; medical health assessment services.

Produits et services

Pharmaceutical products; preparations for medical use; sanitary products for medical use.

Abrégé

The present invention relates to a multiple unit oral dosage form comprising a capsule shell, a first plurality of modified release units of doxylamine or a pharmaceutically acceptable salt thereof and a second plurality of modified release units of pyridoxine or a pharmaceutically acceptable salt thereof, characterized in that said capsule shell does not contain titanium dioxide. It also relates to multiple unit oral dosage form wherein the capsule shell comprises at least one capsule shell material, preferably at least one capsule shell material and at least one organic colourant.

Classes IPC  ?

• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 9/50 - Microcapsules

Produits et services

Management of business projects, namely management of clinical trial projects, recruitment and selection of personnel and experts for clinical trials, business management of clinical trials, arranging service contracts for others; records management services, namely indexing of documents for third parties, especially coordination and control of electronic and paper document flow; data management services to be used in the following fields: pharmaceutical drug development namely preparation of case report forms (CRFs); collection and compilation of data into a central storage in the following fields: clinical trials; compilation and provision of statistical and biostatistical information; medical coding services for third parties, namely coding of clinical trial data for the purposes of medical science and of regulatory reviews and approvals; compilation of data for the purpose of medical science research and medical consultation; regulatory document submission management, namely compiling dossiers in electronic common technical document or common technical document formats, annual reports, management of article submissions. Education; training; organization and execution of conventions, events, congresses, seminars, conferences, symposia, exhibitions; publication of texts; on-line publication of books and specialized magazines; multimedia publication of magazines, specialized magazines and newspapers; arranging and organization of meetings, workshops and events; regulatory document submission management, namely publishing presentations. Scientific and technological services; scientific services and research related to the same; scientific services and design related to the same; platform as a service [PAAS] comprising software platforms for the transmission of images, audiovisual content, video content and messages; scientific research for medical purposes; research services, design and development of instruments for control and diagnostics; computer diagnostic services, computer analysis services; scientific research; electronic data storage; technical writing, namely medical writing services for the development of medical protocols, clinical study reports, researcher pamphlets, safety reports, informed consent forms, meeting summaries, posters, manuscripts, study diagrams, manuals, and literature reviews; providing online non-downloadable software featuring clinical study and clinical trial management system tools via a website; electronic storage of files and documents; providing online non-downloadable software featuring study management files; programming of software for study management files; electronic storage services for archiving temporary files throughout the clinical study lifecycle; scientific research, namely programming of software for biostatistics, development of protocols for sample size and statistical power calculations, randomization plans, statistical analysis plans, programming of software for validation in a statistical analysis system, providing online non-downloadable software enabling interpretation and reporting of data for clinical trial reports and publications, product development for others; scientific research, namely intermediate analysis for early decision making, providing online non-downloadable software featuring database and data lists ready for a New Drug Application (NOA), regulatory submission-compliant data files, study data tabulation and data on model regulatory submission standards; medical research and development for new products for others in the field of medical surveillance and safety plans, ongoing oversight of patient-level studies and review of safety data, interpretation of study protocol, consultation on potential safety and medical issues and 24/7 medical surveillance coverage; drug development; drug discovery of adverse events from clinical trials, development of safety update reports and other aggregate reports, development of management safety plans and medical surveillance plans; quality testing of clinical trial's documentation, for example, standard operating procedures (sops) and work instructions, internal system reviews, site audits, provider evaluations; medical research in the following areas: pharmacology namely simulation, dose selection and optimization, biomarker and endpoint selection, study design optimization, population pharmacokinetic and pharmacodynamic modeling, exposure response modeling; medical research; information related to scientific and medical research in the area of clinical trials, namely the design of clinical trials and outcome measures for studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; conducting clinical trials for third parties studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; custom computer programming related to the following fields: image training and integration into computer systems of suitability data with interactive response technology (IRT); design and development of computer databases for the collection, storage, management, analysis and validation of data for use in the medical and pharmaceutical fields; electronic storage services for archiving presentations. Regulatory compliance consultancy, namely legal assistance to third parties in drafting and compiling applications for new drugs, legal services relating to the submission and life cycle management of clinical trial applications to competent authorities, to ethics committees and to regulatory agencies, legal assistance concerning submission of amendments to applications.

Produits et services

Pharmaceuticals, medical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals.

Produits et services

Pharmaceutical preparations for the treatment of motor neuron diseases

Produits et services

Pharmaceuticals, medical preparations.

Abrégé

The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunotherapy of tumors and in the treatment of one or more HDAC6-mediated diseases.

Classes IPC  ?

• A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux

Produits et services

Productos farmacéuticos, preparaciones para uso médico y veterinario; productos higiénicos y sanitarios para uso médico; alimentos y sustancias dietéticas para uso médico o veterinario, alimentos para bebés; suplementos alimenticios para personas o animales.

Produits et services

Pharmaceutical and veterinary products; hygienic and sanitary products for medical use; dietetic food and substances for medical or veterinary use, food for babies; nutritional supplements for humans and animals.

Produits et services

Dietetic food and substances for medical or veterinary use; food for babies; food supplements for humans or animals.

Produits et services

Pharmaceutical products for gynecological use, pharmaceutical products for dermatological use; hygienic and sanitary products for medical use; cosmetic products for medical use; dietetic food and substances for medical or veterinary use, food for babies; nutritional supplements for humans and animals.

Produits et services

Biochemical and chemical preparations for medical use namely chemical reagents for medical purposes and excipients in liquid formulation for oral administration; Biological preparations for medical use for treating neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, chronic juvenile idiopathic arthritis, polycythemia vera, Di Guglielmo's disease, leukemia, myelomas, myelosclerosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.

Produits et services

Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders

Produits et services

Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, duchenne muscular dystrophy, becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders.

Produits et services

(1) Management of business projects, namely management of clinical trial projects, recruitment and selection of personnel and experts for clinical trials, business management of clinical trials, arranging service contracts for others; records management services, namely indexing of documents for third parties, especially coordination and control of electronic and paper document flow; data management services to be used in the following fields: pharmaceutical drug development namely preparation of case report forms (CRFs); collection and compilation of data into a central storage in the following fields: clinical trials; compilation and provision of statistical and biostatistical information; medical coding services for third parties, namely coding of clinical trial data for the purposes of medical science and of regulatory reviews and approvals; compilation of data for the purpose of medical science research and medical consultation; regulatory document submission management, namely compiling dossiers in electronic common technical document or common technical document formats, annual reports, management of article submissions. (2) Education; training; organization and execution of conventions, events, congresses, seminars, conferences, symposia, exhibitions; publication of texts; on-line publication of books and specialized magazines; multimedia publication of magazines, specialized magazines and newspapers; arranging and organization of meetings, workshops and events; regulatory document submission management, namely publishing presentations. (3) Scientific and technological services; scientific services and research related to the same; scientific services and design related to the same; platform as a service [PAAS] comprising software platforms for the transmission of images, audiovisual content, video content and messages; scientific research for medical purposes; research services, design and development of instruments for control and diagnostics; computer diagnostic services, computer analysis services; scientific research; electronic data storage; technical writing, namely medical writing services for the development of medical protocols, clinical study reports, researcher pamphlets, safety reports, informed consent forms, meeting summaries, posters, manuscripts, study diagrams, manuals, and literature reviews; providing online non-downloadable software featuring clinical study and clinical trial management system tools via a website; electronic storage of files and documents; providing online non-downloadable software featuring study management files; programming of software for study management files; electronic storage services for archiving temporary files throughout the clinical study lifecycle; scientific research, namely programming of software for biostatistics, development of protocols for sample size and statistical power calculations, randomization plans, statistical analysis plans, programming of software for validation in a statistical analysis system, providing online non-downloadable software enabling interpretation and reporting of data for clinical trial reports and publications, product development for others; scientific research, namely intermediate analysis for early decision making, providing online non-downloadable software featuring database and data lists ready for a New Drug Application (NOA), regulatory submission-compliant data files, study data tabulation and data on model regulatory submission standards; medical research and development for new products for others in the field of medical surveillance and safety plans, ongoing oversight of patient-level studies and review of safety data, interpretation of study protocol, consultation on potential safety and medical issues and 24/7 medical surveillance coverage; drug development; drug discovery of adverse events from clinical trials, development of safety update reports and other aggregate reports, development of management safety plans and medical surveillance plans; quality testing of clinical trial's documentation, for example, standard operating procedures (sops) and work instructions, internal system reviews, site audits, provider evaluations; medical research in the following areas: pharmacology namely simulation, dose selection and optimization, biomarker and endpoint selection, study design optimization, population pharmacokinetic and pharmacodynamic modeling, exposure response modeling; medical research; information related to scientific and medical research in the area of clinical trials, namely the design of clinical trials and outcome measures for studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; conducting clinical trials for third parties studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; custom computer programming related to the following fields: image training and integration into computer systems of suitability data with interactive response technology (IRT); design and development of computer databases for the collection, storage, management, analysis and validation of data for use in the medical and pharmaceutical fields; electronic storage services for archiving presentations. (4) Regulatory compliance consultancy, namely legal assistance to third parties in drafting and compiling applications for new drugs, legal services relating to the submission and life cycle management of clinical trial applications to competent authorities, to ethics committees and to regulatory agencies, legal assistance concerning submission of amendments to applications.

Produits et services

Management of business projects, namely management of clinical trial projects in the nature of providing information management services; recruitment and selection of personnel and experts for clinical trials; business management of clinical trials; outsourcing services in the nature of arranging service contracts for others in the field of pharmaceutical development and clinical research; records management services, namely indexing of documents for third parties, especially coordination and control of electronic and paper document flow; database management services in the field of pharmaceutical product development, namely, preparation of case report forms (CRFs); collection and compilation of data into a central storage in the field of clinical trials; compilation and provision of statistical and biostatistical information in the nature of statistical analysis and reporting services for business purposes; medical coding services for third parties, namely coding of clinical trial data for the purposes of medical science and of regulatory reviews and approvals in the nature of compilation and systemization of information into computer databases; compilation of data into computer databases for the purpose of medical science research and medical consultation; regulatory document submission management, namely compiling dossiers in electronic common technical document formats, annual reports, management of article submissions in the nature of records management services, namely document indexing for others. Education services, namely conducting seminars, conferences, workshops, and training sessions in the field of clinical trial management, pharmaceutical development, and regulatory compliance; training services in the field of clinical trial coordination, biostatistics, and data management; organization and execution of conventions, events, congresses, seminars, conferences, symposia, and exhibitions in the field of pharmaceutical and medical research; publication of texts, other than publicity texts; on-line publication of books and specialized magazines; multimedia publication of magazines, specialized magazines and newspapers; arranging and organization of meetings in the nature of seminars, workshops and social entertainment events, namely networking events in the field of pharmaceutical drug development and clinical research; regulatory document submission management, namely publishing presentations as printed matter. Scientific and technological services namely scientific research, analysis, testing, and data computer modeling services in the field of pharmaceutical development, clinical trials, and medical technology; scientific services and scientific research, namely conducting scientific pharmaceutical product feasibility studies and product designing medical devices and instruments for clinical trials; scientific services and product design, namely conducting scientific pharmaceutical product feasibility studies and designing medical devices and instruments for clinical trials; platform as a service (PAAS) comprising software platforms for the transmission of images, audiovisual content, video content and messages; scientific research for medical purposes; product research services, design and development of instruments for control and diagnostics; computer diagnostic services, computer system analysis services; scientific research; electronic data storage; technical writing, namely medical writing services for clinical protocols, study reports, and regulatory dossiers; providing online non-downloadable software featuring clinical study and clinical trial management system tools via a website; electronic storage of files and documents; providing online non-downloadable software providing access to study management files; programming of software for study management files and electronic storage services for archiving temporary files throughout the clinical study lifecycle; scientific research, namely programming of software for biostatistics, development of protocols for sample size and statistical power calculations, randomization plans, and statistical analysis plans; providing online non-downloadable software enabling interpretation and reporting of data for clinical trial reports and publications; product development for others; scientific research, namely intermediate analysis for early decision-making in clinical trials; providing online non-downloadable software for providing access to databases and data lists ready for a New Drug Application (NDA), regulatory submission-compliant data files, study data tabulation, and data on model regulatory submission standards; medical research and development for new products for others in the field of medical surveillance and safety plans; pharmaceutical drug development services; drug discovery services of adverse events from clinical trials; pharmaceutical drug development services, namely development of safety update reports, management safety plans, and medical surveillance plans; product quality testing of clinical trial's documentation, for example, standard operating procedures (SOPs) and work instructions, internal system reviews, site audits, provider evaluations; medical research in the field of pharmacology, namely study design optimization, and modeling of pharmacokinetic population and pharmacodynamic interactions; Information related to scientific and medical research in the area of clinical trials, namely the design of clinical trials and outcome measures for studying human diseases, or studying or testing drugs, devices, or medical treatment methods on humans; Custom computer programming in the field of image training and integration into computer systems of suitability data with interactive response technology (IRT); Product design and development of computer databases for the collection, storage, management, analysis, and validation of data for use in the medical and pharmaceutical fields; Electronic data storage services for archiving presentations. Regulatory compliance consultancy, namely legal assistance to third parties in drafting and compiling applications for new drugs; legal services relating to the submission and lifecycle management of clinical trial applications to competent authorities, ethics committees, and regulatory agencies; legal assistance concerning the submission of amendments to applications for regulatory approval.

Produits et services

Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders.

Abrégé

The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).

Classes IPC  ?

• C07D 249/06 - Triazoles-1, 2, 3Triazoles-1, 2, 3 hydrogénés avec des radicaux aryle liés directement aux atomes du cycle
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 403/10 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 417/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 471/04 - Systèmes condensés en ortho
• A61K 31/4192 - 1,2,3-Triazoles
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 27/02 - Agents ophtalmiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Produits et services

Business project management, That is, project management of clinical studies, recruitment and selection of clinical study sites and investigators, management of clinical study sites and clinical monitoring, managing relationships between vendors and subcontractors, organization and planning of meetings, workshops and events; Records management services, namely, document indexing for others, In particular bathtubs, coordinating and controlling flow of electronic and paper documents; Data management services for use in the following fields: pharmaceuticals drug development, That is, preparation of Case Report Forms (CRFs), Collection and compilation of information into computer databases in the following fields: Clinical studies; Compilation and provision of statistical and biostatistical information. Teaching; Training; Arranging and conducting of conventions, events, congresses, seminars, conferences, symposia, exhibitions; Publication of texts; Online publication of specialist magazines and books; Multimedia publishing of magazines, journals and newspapers. Science and technology services; Scientific services and research relating thereto; Scientific services and design relating thereto; Platform as a service [PaaS] featuring software platforms for transmission of images, audio-visual content, video content and messages; Scientific investigation for medical purposes; Research, design and development of monitoring and diagnostic tools; Computer analysis, prediction and diagnostics; Scientific research; Electronic data storage; Technical writing, namely, medical writing services for developing medical protocols, clinical study reports, investigator brochures, safety reports, informed consent forms, meeting abstracts, posters, manuscripts, study charts, manuals and literature reviews; Providing an Internet website portal featuring clinical study and clinical trial management system tools; Electronic storage of files and documents, trial management files (TMF), TMF setup, archiving and management of TMP files through lifecycle of clinical study; Research services, namely, biostatistics and statistical programming, protocol development of sample size and power calculations, randomization schedules, statistical analysis plans, statistical programming and validation in statistical analysis system, statistical analyses, interpretation and reporting of data for clinical trial reports and publications, statistical and strategic consulting for product development; Research services, Namely, interim analysis for early decision-making, database integration, New Drug Application (NDA) ready data listings, regulatory submission compliant datasets, thought leadership and operational experience with study data tabulation model and analysis data model regulatory submission standards; Research services, Namely, integrated safety and efficacy summaries, adaptive design consulting and simulation support, translational research support data monitoring board management and support; Medical research, Namely, medical surveillance and search site surveillance in the field of medical revision of clinical study materials, preparation of medical surveillance and safety plans, continuous monitoring of patient studies and revision of safety data; Medical research, Namely, support in subject suitability for researchers, medical support to sites and study groups for the interpretation of study protocols, consultancy on potential security problems and medical problems and 24/7 medical surveillance; Pharmaceutical drug development services; drug safety, In particular computer-assisted, processing adverse events from clinical trials, preparing Development Safety Update Reports (DSURs) and other aggregate reports, performing signal detection and benefit-risk assessments, preparing safety management plans and preparing medical monitoring plans; Providing quality assurance services in the following fields: Clinical trials, namely, quality assistance documentation, For example, Standard Operating Procedures (SOPs) and work instructions, internal system reviews, site audits, vendor assessments; Medical research in the following fields: Pharmacology, namely, dose simulation, selection and optimization, selection of biomarkers and endpoints, optimization of trial design, population pharmacokinetic and pharmacodynamic modeling, exposure response modeling; Medical research; Providing medical and scientific research information in the field of clinical trials, namely, the design of clinical trials and outcome measures for studying human diseases, or for studying or testing drugs, devices or methods of medical treatment on humans; Conducting clinical trials for others which study human diseases, or study or test drugs, devices or methods of medical treatment on humans; Custom computer programming services, in relation to the following fields: imaging adjudication and computer systems integration of eligibility data with Interactive Response Technology (IRT); Computer database design and implementation for data collection, data storage, data management, data analysis, and data validation, for use in the following fields: medical field and Pharmaceutical field; Compilation of data For research purposes, in relation to the following fields: medical science and Provision of technical advice and consultation services; Medical coding for others, namely, coding of clinical trial data for purposes of medical science and regulatory review and approvals. Regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies, submission planning and life cycle management of clinical trial applications to Competent Authorities, Ethics Committees and Regulatory Agencies, pre-approval submissions, submission of supplements, amendments and variations applications; Regulatory submission management, namely, submission publishing and dossier compilation in electronic common technical document or common technical document formats, annual reports, paper submissions management and submission archival.

Abrégé

The present invention relates to selective oxadiazole-based inhibitors of histone deacetylase 6 (HDAC6) and uses thereof in treating various diseases and disorders.

Classes IPC  ?

• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• A61K 31/4245 - Oxadiazoles
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole

Produits et services

(1) Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders.

Produits et services

(1) Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, duchenne muscular dystrophy, becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders.

Abrégé

A process for obtaining {{6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%. A process for obtaining {{6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4-(hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%. An HPLC method for determining the purity of the product and possible impurities thereof is also described.

Classes IPC  ?

• C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
• C07C 269/06 - Préparation de dérivés d'acide carbamique, c.-à-d. de composés contenant l'un des groupes l'atome d'azote ne faisant pas partie de groupes nitro ou nitroso par des réactions n'impliquant pas la formation de groupes carbamate
• B01J 20/286 - Phases reliées chimiquement à un substrat, p. ex. à de la silice ou à des polymères
• C07C 269/08 - SéparationPurificationStabilisationEmploi d'additifs

Abrégé

The present invention relates to novel selective oxadiazole-based inhibitors of histone deacetylase 6 (HDAC6) bearing a pentaheterocyclic scaffold and pharmaceutical compositions thereof.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 413/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
• C07D 487/04 - Systèmes condensés en ortho
• C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
• C07D 495/04 - Systèmes condensés en ortho
• C07D 471/10 - Systèmes condensés en spiro
• C07D 487/10 - Systèmes condensés en spiro
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles

Abrégé

The present invention relates to the use of the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof in the treatment of SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer.More specifically, the present invention provides to the use of pharmaceutical compositions comprising the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof and at least one physiologically acceptable excipient in the treatment of a patient affected by SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer.

Classes IPC  ?

• A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as "gene expression signatures", in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl)benzamide.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Abrégé

The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as "gene expression signatures", in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1 H-tetrazol-1 -yl)methyl)benzamide.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer

Produits et services

Medicines to treat insomnia; sleep aid medicines; food supplements used for insomnia and as sleep aid in different conditions.

Produits et services

Pharmaceuticals, in particular supplements based on extracts of hawthorn, lavender and hops for treating and/or preventing sleep disturbances, including insomnia and middle-of-the-night insomnia; nutritional supplements; nutritional supplements; dietetic substances adapted for medical use.

Produits et services

Drugs for use in digestive system and metabolic disorders.

Produits et services

Pharmaceutical products, preparations for medical use; hygienic and sanitary products for medical use; dietetic substances and foods for medical use, food for babies; food supplements for persons.

Abrégé

The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunotherapy of tumors and in the treatment of one or more HDAC6-mediated diseases.

Classes IPC  ?

• A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunotherapy of tumors and in the treatment of one or more HDAC6-mediated diseases.

Classes IPC  ?

• A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61P 35/00 - Agents anticancéreux
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

A process for obtaining {{6-[(diethylamino)methyl]naphthalen-2-yl}methyl[4-(hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%. An HPLC method for determining the purity of the product and possible impurities thereof is also described.

Classes IPC  ?

• C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
• B01J 20/286 - Phases reliées chimiquement à un substrat, p. ex. à de la silice ou à des polymères
• C07C 269/06 - Préparation de dérivés d'acide carbamique, c.-à-d. de composés contenant l'un des groupes l'atome d'azote ne faisant pas partie de groupes nitro ou nitroso par des réactions n'impliquant pas la formation de groupes carbamate
• C07C 269/08 - SéparationPurificationStabilisationEmploi d'additifs
• G01N 30/02 - Chromatographie sur colonne

Produits et services

Food supplements; Nutraceuticals; Probiotic supplements; Functional food for improvement of basal glycaemia and insulin resistance in patients prone to developing type 2 diabetes; Banaba-based supplements, linked to chromium picolinate.

Produits et services

Food supplements; Nutraceuticals; Probiotic supplements; Functional food for improvement of basal glycaemia and insulin resistance in patients prone to developing type 2 diabetes; Banaba-based supplements, linked to chromium picolinate.

Produits et services

Food supplements; Nutraceuticals; Probiotic supplements; Functional food for improvement of basal glycaemia and insulin resistance in patients prone to developing type 2 diabetes; Banaba-based supplements, linked to chromium picolinate.

Produits et services

Pharmaceutical products, preparations for medical use; sanitary products for medical use.

Produits et services

Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders

Produits et services

Pharmaceutical preparations; chemical and biochemical products for medical purposes; Biological preparations for medical use; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.

Produits et services

Pharmaceutical preparations; chemical and biochemical products for medical purposes; Biological preparations for medical use; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.

Abrégé

Compounds of formula (I) as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy, graft rejection, GVHD, myositis, diseases associated with abnormal lymphocyte function, multiple myeloma, non-Hodgkin lymphoma, autoimmune diseases, inflammatory diseases, cancer and neurodegenerative pathologies. Preferred compounds are e.g. 2-(4-((5-(benzo[b]thiophen-3-yl)-1H- tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and related compounds.

Classes IPC  ?

• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 31/4035 - Isoindoles, p. ex. phtalimide
• A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• C07D 413/08 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles alicycliques
• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 471/10 - Systèmes condensés en spiro
• C07D 487/04 - Systèmes condensés en ortho
• C07D 487/10 - Systèmes condensés en spiro

Abrégé

Compounds of formula (I) as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy, graft rejection, GVHD, myositis, diseases associated with abnormal lymphocyte function, multiple myeloma, non-Hodgkin lymphoma, autoimmune diseases, inflammatory diseases, cancer and neurodegenerative pathologies. Preferred compounds are e.g. 2-(4-((5-(benzo[b]thiophen-3-yl)-1H- tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and related compounds.

Classes IPC  ?

• C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 413/08 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles alicycliques
• C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
• C07D 487/04 - Systèmes condensés en ortho
• C07D 487/10 - Systèmes condensés en spiro
• C07D 471/10 - Systèmes condensés en spiro
• A61K 31/4245 - Oxadiazoles
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
• A61K 31/4192 - 1,2,3-Triazoles
• A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
• A61K 31/4035 - Isoindoles, p. ex. phtalimide
• A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles

Produits et services

Pharmaceuticals; Pharmaceutical specialities for use in treating mild to moderate dementia caused by Alzheimer's disease; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases, generated by or acting on the central nervous system; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases.

Produits et services

Medicine, Dietetic food and substances Eyepatches for medical purposes; Food supplements for human beings.

Produits et services

Medicine, Dietetic food and substances Eyepatches for medical purposes; Food supplements for human beings.

Produits et services

Pharmaceuticals; Pharmaceutical specialities for use in treating mild to moderate dementia caused by Alzheimer's disease; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases, generated by or acting on the central nervous system; Pharmaceutical preparations for the treatment of central nervous system [CNS] diseases.

Abrégé

The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.

Classes IPC  ?

• A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine
• A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 31/497 - Pyrazines non condensées contenant d'autres hétérocycles
• A61K 31/4245 - Oxadiazoles
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 31/433 - Thiadiazoles
• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• C07D 249/12 - Atomes d'oxygène ou de soufre
• C07D 249/08 - Triazoles-1, 2, 4Triazoles-1, 2, 4 hydrogénés
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 271/06 - Oxadiazoles-1, 2, 4Oxadiazoles-1, 2, 4 hydrogénés
• C07D 271/10 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés
• C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 471/04 - Systèmes condensés en ortho
• C07D 257/04 - Cycles à cinq chaînons
• C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 495/04 - Systèmes condensés en ortho
• C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• A61P 35/00 - Agents anticancéreux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 27/00 - Médicaments pour traiter les troubles des sens
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C07D 271/113 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
• C07D 285/125 - Thiadiazoles-1, 3, 4Thiadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
• C07D 491/107 - Systèmes condensés en spiro avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène

Abrégé

Method of treating Philadelphia-negative myeloproliferative syndromes in a patient suffering therefrom by administering to the patient diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount of from 50 to 100 mg per patient.

Classes IPC  ?

• A61K 31/27 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carbamiques ou thiocarbamiques, p. ex. méprobamate, carbachol, néostigmine
• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61K 31/16 - Amides, p. ex. acides hydroxamiques
• A61K 31/18 - Sulfamides
• A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Produits et services

Pharmaceutical drugs for alleviating symptoms of intermittent claudication in peripheral vascular disease; Pharmaceutical drugs for preventing re-occlusions after revascularisation procedures; Antithrombotics, antiplatelet drugs.

Produits et services

Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders

Produits et services

Biochemical and chemical preparations for medical use, namely, chemical reagents for medical purposes and excipients in a liquid formulation for oral administration; biological preparations for medical use for the treatment of neurological and psychiatric diseases, cancer, inflammatory diseases, HIV/AIDS, spinal muscular atrophy, systemic juvenile idiopathic arthritis, polycythaemia vera, essential thrombocythemia, leukemias, myelomas, myelofibrosis, Duchenne muscular dystrophy, Becker muscular dystrophy and other forms of muscular dystrophy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders; pharmaceutical products for the treatment of genetic disorders

Produits et services

Pharmaceutical specialities; chemical and biochemical products for medical purposes; Biological preparations for medical use; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.

Produits et services

Pharmaceutical preparations; chemical and biochemical products for medical purposes; Biological preparations for medical use; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.

Produits et services

Pharmaceutical specialities except antimycotics; chemical and biochemical products for medical purposes except antimycotics; Biological preparations for medical use except antimycotics; Pharmaceuticals for the treatment of neuromuscular diseases and disorders; Pharmaceuticals for the treatment of genetic diseases.

Produits et services

Pharmaceutical specialities for use in treating mild to moderate dementia caused by Alzheimer's disease; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases, generated by or acting on the central nervous system.

Abrégé

In a preferred embodiment, there is provided A process for preparing {6[

Classes IPC  ?

• C07C 269/06 - Préparation de dérivés d'acide carbamique, c.-à-d. de composés contenant l'un des groupes l'atome d'azote ne faisant pas partie de groupes nitro ou nitroso par des réactions n'impliquant pas la formation de groupes carbamate
• C07C 269/08 - SéparationPurificationStabilisationEmploi d'additifs
• C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé

Abrégé

A process for obtaining { {6-[(diethylamino)methyljnaphthalen-2-yl}methyl [4- (hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%. An HPLC method for determining the purity of the product and possible impurities thereof is also described.

Classes IPC  ?

• C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé

Abrégé

A process for obtaining {{6-[(diethylamino)methyl]naphthalen-2-yl}methyl [4- (hydroxycarbamoyl)phenyl]carbamate and/or pharmaceutically acceptable salts thereof having high purity is described. This process allows to obtain a product having an amount of any single unknown impurity equal to or less than 0.10%, as well as a product having a purity greater than 99.5%, preferably equal to or greater than 99.6%. An HPLC method for determining the purity of the product and possible impurities thereof is also described.

Classes IPC  ?

• C07C 269/06 - Préparation de dérivés d'acide carbamique, c.-à-d. de composés contenant l'un des groupes l'atome d'azote ne faisant pas partie de groupes nitro ou nitroso par des réactions n'impliquant pas la formation de groupes carbamate
• C07C 269/08 - SéparationPurificationStabilisationEmploi d'additifs
• C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé

Produits et services

Pharmaceutical and veterinary preparations; Sanitary products for medical use; Foodstuffs and dietetic substances for medical or veterinary purposes; Dietetic supplements for human or animal use; Food for babies.

Produits et services

Pharmaceutical products, preparations for medical use; sanitary products for medical use.

Produits et services

Medicine; Medicines for human purposes; Chemico-pharmaceutical preparations; Chemico-pharmaceutical preparations; Diagnostic agents for medical use; Diagnostic agents for pharmaceutical use; Medicated food supplements; Medical preparations; Medicinal substances; Medicinal ointments; Hormone preparations for pharmaceutical use; Mixed hormone preparations; Gastrointestinal preparations; anti-emetic products; Anti-emetics; Anti-nauseants; Preparations against morning sickness; Preparations against pregnancy-related illnesses; Preparations against discomfort in pregnancy; Preparations to treat hormone-related illnesses; Preparations to treat anxiety and stress-related illnesses; Preparations to increase physical wellbeing in pregnancy; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Preparations for vein disorders; Anti-thrombosis preparations; Preparations to inhibit blood clotting; Preparations to treat venous thromboembolism; Preparations to prevent venous thromboembolism illnesses; Preparations to treat deep vein thrombosis; Preparations to treat lung embolism; Preparations to prevent blood clotting; Preparations to treat acute coronary syndrome; Pharmaceutical products and preparations to prevent swelling in the legs; Plant extracts for pharmaceutical purposes; Herbal supplements; Pharmaceuticals; Pharmaceutical compositions; Pharmaceutical preparations for human use; Pharmaceutical preparations and substances; Pharmaceutical preparations; Pharmaceutical preparations for use in oncology; Pharmaceuticals for gynaecology; Pharmaceutical preparations for cardiology; Chemical preparations for the diagnosis of pregnancy; Hormones for medical purposes; Hormone suppressing preparations; Pharmaceutical preparations for the prevention of disorders of the endocrine system; Pharmaceutical preparations for the treatment of disorders of the endocrine system; Cardiovascular pharmaceuticals; Gastrointestinal preparations; Pre-filled syringes for medical purposes; Filled syringes for medical purposes [containing pharmaceuticals]; Injectable pharmaceuticals; Injection solutions in a syringe. Preparing audio-visual presentations for use in advertising; audiovisual advertisements; Preparation of advertising material; Information services relating to advertising; Outdoor advertising; Banner advertising; Computerised business promotion; Digital marketing; Analysis of advertising response and market research; Preparation of publicity publications; Web indexing for commercial or advertising purposes; Advertising services provided via the internet; Marketing; Marketing and promotion services; Internet marketing; Search engine marketing services; Trade fairs and exhibitions; Merchandising; Public relations services; Online advertisements; Web site traffic optimization; Search engine optimisation; On-line advertising and marketing services; Planning services for advertising; Press advertising services; Production of advertising matter and commercials; Product marketing; Product demonstrations and product display services; Collection of information relating to advertising; Writing, preparing and publication of texts for advertising purposes; Trade promotional services; Promotional marketing; Sales promotion using audiovisual media; Publicity and sales promotion services; Publication of publicity materials; Distribution of advertising, marketing and promotional material; Advertising; Publicity and sales promotion services; Advertising; Advertising via electronic media and specifically the internet; Advertising in periodicals, brochures and newspapers; Advertising business especially in the field of telematic and telephone networks; Advertising services provided via a data base; Direct marketing; Advertising and marketing; Advertising; Direct mail advertising; Direct mail advertising; Dissemination of advertising matter online; Dissemination of advertisements via the Internet; Dissemination of advertisements; Advertising by mail order; Consultancy and support in the field of advertising; Advice relating to marketing management; Mediation and conclusion of commercial transactions for others; Provision of information concerning commercial sales; Provision of information and advisory services relating to e-commerce; Subscription services; Ordering services; Ordering services for third parties; Wholesale ordering services; Computerized on-line ordering services; Computerised stock ordering; Import-export agency services; Comparison shopping services; Electronic order processing; Providing market information in relation to consumer products; Import-export agency services; Information about sales methods; Commercial administration of the licensing of the goods and services of others; Loyalty, incentive and bonus program services; Providing consumer product advice; Online ordering services; Price comparison services; Telephone order-taking services for others; Telemarketing services; Sales administration; Mediation of agreements regarding the sale and purchase of goods; Intermediary services relating to advertising; Business management; Office functions; Office functions services; Computerised office management; Business management; Business management services relating to electronic commerce; Business administration and management; Business management of wholesale and retail outlets; Business management; Commercial assessment; Organising of business contacts; Collective buying; Negotiation and conclusion of commercial transactions for third parties via telecommunication systems; Commercial intermediation services; Administration of foreign business affairs; Commercial management; Customer relationship management; Balance sheet accounting; Book-keeping and accounting services; Bookkeeping for electronic funds transfer; Book-keeping; Drawing up of statements of accounts; Book-keeping; Administrative data processing; Data processing, systematisation and management; Addressing of envelopes; Clerical services for the taking of sales orders; Business records keeping; Market surveys conducted by telephone; Telephone answering for unavailable subscribers; Word processing and typing services; Word processing; Preparation of mailing lists; Drawing up of business statistical information; Computerized file management; Information services relating to data processing; Business analysis, research and information services; Cost-price analysis; Marketing studies; Computerised inventory control; Acquisition of business information relating to company activities; Computerised data processing; Computerised stock management; Computerised compilation of order lists; Computerised compilation of stock control records; Computerised compilation of customer indexes; Computerized file management; Computerized file management; Collection and systematisation of information into computer databases; Compilation of statistics; Administrative processing of purchase orders; Personnel management and Staff restructuring; Collection of data; Collecting information for business; Collection and systematization of business data; Sales volume tracking for others; Business records management; Telephone switchboard services; Business consultancy and advisory services; Rental of objects in connection with the providing of the aforesaid services, included in this class; Consultancy and information in relation to the aforesaid services, included in this class. Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consultancy relating to pharmaceutical research and development; Consultancy relating to research and development in the field of therapeutics; Consultancy relating to laboratory testing; Providing information about the results of clinical trials for pharmaceutical products; Pharmaceutical product evaluation; Biological research, clinical research and medical research; Biomedical research services; Scientific and technological services in the field of safety of medicines; Medical research laboratory services; Medical laboratory services; Services for assessing the efficiency of pharmaceuticals; Testing of pharmaceuticals; Conducting early evaluations in the field of new pharmaceuticals; Conducting clinical trials for pharmaceutical products; Clinical research; Development of pharmaceutical preparations and medicines; Pharmaceutical products development; Research and development of vaccines and medicines; Providing information on clinical studies via an interactive website; Providing scientific information in the field of medical disorders and their treatment; Research on the subject of pharmaceuticals; Research on the subject of pharmaceuticals; Clinical research; Clinical trials; Clinical trials; Medical research; Pharmaceutical drug development services; Pharmaceutical research and development; Inspection of pharmaceuticals; Scientific research and development; Advisory services relating to chemical reagents; Advisory services relating to biochemistry; Chemical analysis; Analysis of product development; Analysis of product design; Authentication services; Quality assurance consultancy; Consultancy services relating to quality control; Product quality evaluation; Computer aided scientific testing; Computer aided diagnostic testing services; Computer aided industrial testing; Quality checking and testing; Quality audits; Scientific testing services; Scientific testing services; Development of testing methods; Process monitoring for quality assurance. Therapy; Monitoring of patients; Professional consultancy relating to health; Medical services; Medical and healthcare clinics; Medical services; Medical information services provided via the Internet; Medical counseling relating to stress; Medical consultancy relating to oncology; Medical consultancy relating to cardiology; Medical consultancy relating to gynaecology; Pharmaceutical services; Medical information; Health advice and information services; Provision of information relating to medicine; Medication counseling; Physician services; Medical care; Advisory services relating to medical problems; Providing information to patients in the field of administering medications; Advisory services relating to medical services; Providing news and information in the field of medicine; Medical counseling; Medical consultations; Consultancy and information services relating to medical products; Providing medical support in the monitoring of patients receiving medical treatments; Medical assistance; Medical clinic services; Paramedical services; Services for the preparation of medical reports; Medical screening; Conducting of medical examinations; Physical examination services; Issuing of medical reports; Medical health assessment services; Preparation of reports relating to medical matters; Performing diagnosis of diseases; Medical information; Providing medical information in the healthcare sector; Providing of online information relating to medicines; Providing of information relating to oncology; Providing of information relating to gynaecology; Providing of information relating to cardiology; Medical counseling; Medical evaluation services; Medical diagnostic services; Medical services in the field of oncology; Medical services in the field of gynaecology; Medical services in the field of cardiology; Charitable services, namely providing medical services; Medical assistance; Providing information relating to medical services; Providing information relating to physical examinations; Arranging of medical treatment; Compilation of medical reports; Dispensing of pharmaceuticals; Consultancy and information services provided via the Internet relating to pharmaceutical products; Consultancy and information services relating to pharmaceutical products.

Produits et services

Pharmaceutical products, preparations for medical use; sanitary products for medical use.

Produits et services

Pharmaceuticals, namely pharmaceuticals containing a combination of doxylamine and pyridoxine indicated for managing nausea and vomiting during pregnancy, anti-emetic pharmaceutical preparations.

Abrégé

The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts, isomers and prodrugs thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.

Classes IPC  ?

• C07D 317/60 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• C07D 215/14 - Radicaux substitués par des atomes d'oxygène
• C07D 407/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 213/643 - Phénoxy-2 pyridinesLeurs dérivés
• C07D 209/18 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• A61P 35/00 - Agents anticancéreux
• C07C 259/10 - Composés contenant des groupes carboxyle, un atome d'oxygène d'un groupe carboxyle étant remplacé par un atome d'azote, cet atome d'azote étant lié de plus à un atome d'oxygène et ne faisant pas partie de groupes nitro ou nitroso sans remplacement de l'autre atome d'oxygène du groupe carboxyle, p. ex. acides hydroxamiques ayant des atomes de carbone de groupes hydroxamique liés à des atomes de carbone de cycles aromatiques à six chaînons
• C07D 213/56 - Amides
• C07D 221/04 - Systèmes cycliques condensés en ortho ou en péri
• C07D 233/64 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés substitués, liés aux atomes de carbone du cycle, p. ex. histidine
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 417/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
• A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
• A61K 31/4035 - Isoindoles, p. ex. phtalimide
• A61K 31/443 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
• A61K 31/47 - QuinoléinesIsoquinoléines
• C07D 317/06 - Composés hétérocycliques contenant des cycles à cinq chaînons comportant deux atomes d'oxygène comme uniques hétéro-atomes du cycle comportant les hétéro-atomes en positions 1, 2 condensés avec des carbocycles ou avec des systèmes carbocycliques

Produits et services

Pharmaceuticals, namely pharmaceuticals containing a combination of doxylamine and pyridoxine indicated for managing nausea and vomiting during pregnancy; antiemetic pharmaceutical preparations.

Produits et services

Pharmaceutical products, hygienic and sanitary products for medical use, dietetic substances and food for medical use, food for babies, nutritional supplements for human beings.

Produits et services

Pharmaceutical products; preparations for medical and veterinary use; hygiene and sanitary products for medical use; dietetic food and substances for medical or veterinary use; food for babies; food supplements for humans or animals; plasters, material for dressings; material for filling teeth and dental impressions; disinfectants; products for destroying vermin; fungicides, herbicides.

Abrégé

The present invention provides for a library of vectors comprising human HC-CDR3 regions of varying length, wherein the diversity of said library is focused on the HC-CDR3 region only and diversity has been optimized such that redundancy is reduced for short HC-CDR3 loops and coverage of HC-CDR3 region variants for longer loop lengths has been increased. The library of the present invention is displayed on phage for selection against target antigens.

Classes IPC  ?

• C40B 40/08 - Bibliothèques comprenant de l'ARN ou de l'ADN codant des protéines, p. ex. bibliothèques de gènes
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C40B 40/10 - Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux

Produits et services

Pharmaceuticals, In particular supplements based on myo-inositol, folic acid and α-lactalbumin, for use by inositol-resistant PCOS patients, Nutritional supplements; Nutritional supplements; Dietetic substances adapted for medical use.

Produits et services

Pharmaceuticals, In particular supplements based on myo-inositol, 1D-chiro-inositol, folic acid and α-lactalbumin, for use by patients who are inositol-resistant for the adjuvant treatment of polycystic ovary syndrome, insulin-resistant conditions, pre-diabetic conditions, type 2 diabetes and gestational diabetes; Nutritional supplements; Nutritional supplements; Dietetic substances adapted for medical use.

Produits et services

Pharmaceuticals, medical preparations; Dietetic food and substances adapted for medical use, food for babies; Food supplements for human beings.

Produits et services

Pharmaceuticals, Namely pharmaceuticals containing a combination of doxylamine and pyridoxine indicated for managing nausea and vomiting during pregnancy; Anti-emetic pharmaceutical preparations.

Produits et services

Pharmaceuticals, medical preparations; Sanitary products for medical use.

Produits et services

Pharmaceuticals, medical preparations; Sanitary products for medical use.

Produits et services

Pharmaceuticals, medical preparations; Sanitary products for medical use; all the above only applied for the treatment of schizophrenia, bipolar disorder, major depressive disorder and as a sedative drug.

Produits et services

Pharmaceuticals for use against digestive and metabolic disorders.

Produits et services

Pharmaceuticals for use against digestive and metabolic disorders.

Produits et services

Pharmaceuticals, Namely pharmaceuticals containing a combination of doxylamine and pyridoxine indicated for managing nausea and vomiting during pregnancy; Anti-emetic pharmaceutical preparations.

Produits et services

Pharmaceuticals, in particular supplements based on extracts of hawthorn, lavender and hops for treating and/or preventing sleep disturbances, including insomnia and middle-of-the-night insomnia; Nutritional supplements; Nutritional supplements; Dietetic substances adapted for medical use.

Produits et services

Pharmaceuticals, in particular supplements based on extracts of hawthorn, lavender and hops for treating and/or preventing sleep disturbances, including insomnia and middle-of-the-night insomnia; Nutritional supplements; Nutritional supplements; Dietetic substances adapted for medical use.

Abrégé

Physically and chemically stable oral liquid formulations of Givinostat (Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride) are disclosed, together with methods for the preparation thereof. Such oral formulations are in the form of aqueous suspensions and contain Givinostat and/or pharmaceutically acceptable salts and/or derivatives thereof, at least a wetting agent and/or at least a density-imparting agent. Such formulations are suitable for oral administration for systemic therapeutic action.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
• A61K 9/10 - DispersionsÉmulsions
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
• A61P 7/02 - Agents antithrombotiquesAnticoagulantsAnti-agrégants plaquettaires
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• A61K 31/325 - Acides carbamiquesAcides thiocarbamiquesLeurs anhydrides ou sels
• A61K 47/02 - Composés inorganiques
• A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine

Abrégé

The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.

Classes IPC  ?

• C07D 249/12 - Atomes d'oxygène ou de soufre
• A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4245 - Oxadiazoles
• A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
• A61K 31/5375 - 1,4-Oxazines, p. ex. morpholine
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 27/00 - Médicaments pour traiter les troubles des sens
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• C07D 249/08 - Triazoles-1, 2, 4Triazoles-1, 2, 4 hydrogénés
• C07D 257/04 - Cycles à cinq chaînons
• C07D 271/06 - Oxadiazoles-1, 2, 4Oxadiazoles-1, 2, 4 hydrogénés
• C07D 271/10 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés
• C07D 271/113 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 471/04 - Systèmes condensés en ortho
• C07D 495/04 - Systèmes condensés en ortho

Abrégé

The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.

Classes IPC  ?

• C07D 249/12 - Atomes d'oxygène ou de soufre
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4245 - Oxadiazoles
• A61P 35/00 - Agents anticancéreux
• C07D 495/04 - Systèmes condensés en ortho
• C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 271/10 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 405/04 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 471/04 - Systèmes condensés en ortho
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 271/06 - Oxadiazoles-1, 2, 4Oxadiazoles-1, 2, 4 hydrogénés
• C07D 271/113 - Oxadiazoles-1, 3, 4Oxadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
• C07D 249/08 - Triazoles-1, 2, 4Triazoles-1, 2, 4 hydrogénés
• C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
• C07D 257/04 - Cycles à cinq chaînons
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 27/00 - Médicaments pour traiter les troubles des sens
• A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
• A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
• A61K 31/5375 - 1,4-Oxazines, p. ex. morpholine
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles

Produits et services

Pharmaceutical products and more precisely supplements for the treatment of hyperuricaemia; dietary supplements for medical use; food supplements for medical use; vitamin preparations in the form of food supplements; drinks based on dietary supplements; dietary products for medical use.

Abrégé

The present invention provides for a library of vectors comprising human HC-CDR3 regions of varying length, wherein the diversity of said library is focused on the HC-CDR3 region only and diversity has been optimized such that redundancy is reduced for short HC-CDR3 loops and coverage of HC-CDR3 region variants for longer loop lengths has been increased. The library of the present invention is displayed on phage for selection against target antigens.

Classes IPC  ?

• C40B 40/08 - Bibliothèques comprenant de l'ARN ou de l'ADN codant des protéines, p. ex. bibliothèques de gènes
• C40B 40/10 - Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci

Produits et services

(1) Pharmaceuticals and medications for treatment of motor neuron diseases namely amyotrophic lateral sclerosis

Abrégé

The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.

Classes IPC  ?

• C07D 215/14 - Radicaux substitués par des atomes d'oxygène
• A61K 31/16 - Amides, p. ex. acides hydroxamiques
• A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
• A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
• A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
• A61P 35/00 - Agents anticancéreux
• C07C 259/10 - Composés contenant des groupes carboxyle, un atome d'oxygène d'un groupe carboxyle étant remplacé par un atome d'azote, cet atome d'azote étant lié de plus à un atome d'oxygène et ne faisant pas partie de groupes nitro ou nitroso sans remplacement de l'autre atome d'oxygène du groupe carboxyle, p. ex. acides hydroxamiques ayant des atomes de carbone de groupes hydroxamique liés à des atomes de carbone de cycles aromatiques à six chaînons
• C07D 209/18 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• C07D 213/56 - Amides
• C07D 213/643 - Phénoxy-2 pyridinesLeurs dérivés
• C07D 233/64 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés substitués, liés aux atomes de carbone du cycle, p. ex. histidine
• C07D 317/60 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 407/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.

Classes IPC  ?

• C07D 215/14 - Radicaux substitués par des atomes d'oxygène
• C07C 259/10 - Composés contenant des groupes carboxyle, un atome d'oxygène d'un groupe carboxyle étant remplacé par un atome d'azote, cet atome d'azote étant lié de plus à un atome d'oxygène et ne faisant pas partie de groupes nitro ou nitroso sans remplacement de l'autre atome d'oxygène du groupe carboxyle, p. ex. acides hydroxamiques ayant des atomes de carbone de groupes hydroxamique liés à des atomes de carbone de cycles aromatiques à six chaînons
• C07D 317/60 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 407/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 209/18 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
• C07D 213/56 - Amides
• A61K 31/16 - Amides, p. ex. acides hydroxamiques
• A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
• A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
• A61K 31/4406 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 3, p. ex. zimeldine
• A61P 35/00 - Agents anticancéreux
• C07D 213/643 - Phénoxy-2 pyridinesLeurs dérivés
• C07D 233/64 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des radicaux hydrocarbonés substitués, liés aux atomes de carbone du cycle, p. ex. histidine

Produits et services

Pharmaceutical products, preparations for medical and veterinary use, hygienic and sanitary products for medical use; dietetic food and substances for medical or veterinary use, food for babies.

Produits et services

Pharmaceutical, veterinary and sanitary products; dietetic substances for medical use, food for babies; plasters, material for dressings; material for dental fillings and dental impressions; disinfectants; products for destroying vermin; fungicides, herbicides.

Produits et services

Pharmaceutical and veterinary products; sanitary products for medical purposes; dietetic substances for medical use, food for babies; plasters, material for dressings; material for dental fillings and for dental impressions; disinfectants; products for destroying vermin; fungicides, herbicides.

Produits et services

Pharmaceutical products; hygienic and sanitary preparations for medical use; dietetic food and substances for medical or veterinary use; food for babies; food supplements for humans or animals.

Produits et services

Pharmaceutical products; preparations for medical use; dietetic food and substances for medical or veterinary use; food for babies; food supplements for humans or animals.

Produits et services

Pharmaceuticals, medical preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical use, food for babies; Food supplements for human beings.

Produits et services

Pharmaceuticals; Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical use, food for babies; Food supplements for human beings.

Produits et services

Pharmaceutical products; except pharmaceutical products for skin or hair use; dietetic substances and foodstuffs for medical use; nutritional supplements for humans.